The most controversial topic in the cannabis industry is the green elephant in the room: Cannabis and Hemp are the same plant. Change my mind… Update: November 3, 2019 – My mind was changed, quickly after posting this article on the book of faces. Some science type folks were kind enough to correct my usage… Continue reading What is the Difference Between Hemp and Cannabis?
Josh and his brothers developed a non-psychotropic strain of marijuana which is drastically reducing seizures for pediatric epilepsy patients in Colorado.
The complexity of medical cannabis stems from the millions of combinations of doses and cannabinoid/terpene profiles. Despite this challenge, a systematic and intelligent approach can lead to informed recommendations that most benefit patients. Over time as more research is gathered, these recommendations will become progressively more robust, leading to higher levels of satisfaction with the first recommendation.
More importantly, modulating the activity of the endocannabinoid system turned out to hold therapeutic promise in a wide range of disparate diseases and pathological conditions, ranging from mood and anxiety disorders, movement disorders such as Parkinson’s and Huntington’s disease, neuropathic pain, multiple sclerosis and spinal cord injury, to cancer, atherosclerosis, myocardial infarction, stroke, hypertension, glaucoma, obesity/metabolic syndrome, and osteoporosis, to name just a few.
Wording taken From: 85R1145 GCB-F By: Menéndez S.B. No. 269 A BILL TO BE ENTITLED AN ACT (A)….. (The following information cites at least 2 related Scientific or Medical journals as resources citing topics specifically related to the “qualifying” disease, syndrome, or disability. ) cancer, Cannabinoids as therapeutic agents in cancer: current status and future… Continue reading Applying Science to Senate Bill No. 269 in Texas | Medical Marijuana Bill 2017
Article Outline Narrative review Historical perspective Terminology Cellular drug actions Disputed antiepileptic effects Causal agent in psychosis Cannabis use and cognitive impairment Cannabis use worsens neuropsychologic function in people with multiple sclerosis Cannabis-associated subcortical nuclear gray matter structural changes—neuroimaging Safety concerns Patient Description Discussion Cannabis-associated neuropathology Correlates of cannabis-associated microstructural white matter pathology Is the… Continue reading Adverse Structural and Functional Effects of Marijuana on the Brain: Evidence Reviewed
Amy M. Cohn, Amanda L. Johnson, Shyanika W. Rose, Jessica M. Rath & Andrea C. Villanti Pages 203-213 | Published online: 19 Oct 2016 ABSTRACT Background: As of 2015, more than half of U.S. states have legalized, medicalized, or decriminalized marijuana. Objective: This study examined the prevalence and correlates of support for marijuana legalization in… Continue reading Support for Marijuana Legalization and Predictors of Intentions to Use Marijuana More Often in Response to Legalization Among U.S. Young Adults
Liting Deng, Lindsay Ng, Tatsuya Ozawa and Nephi Stella Journal of Pharmacology and Experimental Therapeutics November 7, 2016, jpet.116.236968; DOI: https://doi.org/10.1124/jpet.116.236968 Abstract Evidence suggests that the non-psychotropic cannabis-derived compound, cannabidiol (CBD), has anti-neoplastic activity in multiple types of cancers, including glioblastoma multiforme (GBM). DNA-damaging agents remain the main standard of care treatment available for patients… Continue reading Quantitative analyses of synergistic responses between cannabidiol and DNA-damaging agents on the proliferation and viability of glioblastoma and neural progenitor cells in culture
Pisanti S1, Malfitano AM2, Ciaglia E2, Lamberti A2, Ranieri R2, Cuomo G2, Abate M2, Faggiana G2, Proto MC3, Fiore D3, Laezza C4, Bifulco M5. Author information 1Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Italy. Electronic address: email@example.com. 2Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Italy.… Continue reading Cannabidiol: State of the art and new challenges for therapeutic applications.
Luciano De Petrocellis, Vittorio Vellani, Aniello Schiano-Moriello, Pietro Marini, Pier Cosimo Magherini, Pierangelo Orlando and Vincenzo Di Marzo Journal of Pharmacology and Experimental Therapeutics June 2008, 325 (3) 1007-1015; DOI: https://doi.org/10.1124/jpet.107.134809 Abstract The plant cannabinoids (phytocannabinoids), cannabidiol (CBD), and Δ9-tetrahydrocannabinol (THC) were previously shown to activate transient receptor potential channels of both vanilloid type 1… Continue reading Plant-Derived Cannabinoids Modulate the Activity of Transient Receptor Potential Channels of Ankyrin Type-1 and Melastatin Type-8